|  |  |  |  |
| --- | --- | --- | --- |
| Risk stratification scores  Variables | REVEAL version 2.0 | COMPERA | FPHR |
| WHO Group I subgroups | + | - | - |
| Demographics (Age, Sex) | + | - | - |
| eGFR | + | - | - |
| NYHA/WHO Functional Class | + | + | + |
| Vital Signs | + | - | - |
| All-cause Hospitalizations ≤ 6months | + |  | - |
| 6-minute walk test | + | + | + |
| NT-proBNP | + | - | - |
| Echocardiogram (pericardial effusion) | + | - | - |
| Pulmonary Function Test (DLco%) | + | - | - |
| Right Heart Catheterization  (PVR, RAP) | (+,+) | (-,+) | (-,+) |
| Cardiac Index | - | + | + |
| Mixed venous oxygen saturation | - | + | - |

**Table 1S**: Variables of REVEAL version 2.0, COMPERA and FPHR risk assessment scores

*COMPERA score: the score developed by the Swedish/Comparative prospective registry of newly initiated therapies for pulmonary hypertension;* *DLco: diffusion capacity of carbon monoxide; eGFR: estimated glomerular filtration rate; FPHR score: the score developed by the French pulmonary hypertension network registry; NT-pro BNP: N terminal-pro b-type natriuretic peptide; NYHA: New York Heart Association; PVR: pulmonary vascular resistance; RAP: right atrial pressure; REVEAL score: The registry to evaluate early and long-term pulmonary arterial hypertension disease management risk score WHO: World Health Organization*